LumiThera today said it has completed its acquisition of Diopsys for an undisclosed amount.
The acquisition of the Pine Brook, N.J.-based electrophysiology medical device maker Diopsys was previously announced on Nov. 11, 2021. Through the deal, Diopsys stockholders will also receive stock in LumiThera and Diopsys will become a wholly-owned subsidiary of the Seattle-based company.
LumiThera will add a complementary diagnosis and monitoring platform, the Valeda light delivery system, to its ocular damage and disease treatment platform. LumiThera’s existing platform uses photobiomodulation for treating age-related macular degeneration. Diopsys’s established commercial sales in the U.S. will combine with LumiThera’s EU sales team to serve a larger global footprint of eye care professionals.
“We are excited for the new combined entity and the potential to prevent vision loss,” Diopsys president and CEO Joe Fontanetta said in a n…